Proteomic analysis of amniotic fluid in pregnancies with Down syndrome

被引:104
作者
Tsangaris, George Th.
Karamessinis, Panagiotis
Kolialexi, Aggeliki
Garbis, Spiros D.
Antsaklis, Aris
Mavrou, Ariadni
Fountoulakis, Michael
机构
[1] Acad Athens, Div Biotechnol, Fdn Biomed Res, Athens 11527, Greece
[2] Univ Athens, Sch Med, Dept Obstet & Gynecol 1, GR-11527 Athens, Greece
关键词
amniotic fluid; biomarkers; Down syndrome; prenatal diagnosis;
D O I
10.1002/pmic.200600085
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Proteomic analysis is widely used for the detection of diagnostic markers. in the present study amniotic fluid supernatants (AFS) from pregnancies with Down syndrome (DS) fetuses and from chromosomally normal fetuses in the 17th week of gestation were analyzed by 2-DE. Gel comparison revealed significant differences in the two groups. Spots with different expression levels were excised and proteins were identified by MALDI-MS and nano-ESI-MS/MS. Splicing factor arginine/serine-rich 4 (SFRS4; Q08170) was present only in AFS from DS fetuses and completely absent in the control group. Quantitative differences were detected for alpha-1-microglobulin (AMBP; P02760), collagen alpha 1 (1) chain (CO1A1; P02452), collagen alpha 1 (III) chain (CO3A1; P02461), collagen alpha 1 (V) chain d (CO5A1; P20908), and basement membrane-specific heparin sulfate proteoglycan core protein (PGBM; P98160). These proteins were increased in cases with DS, whereas protein IBP-1 (P08833) was decreased by 40% compared with chromosomally normal fetuses. Four proteins, CO1A1, CO3A1, CO5A1, and PGBM, appeared as fragments. As differentially expressed proteins were present in all pregnancies with DS tested, they may represent useful potential markers for prenatal diagnosis. However, for protein biomarkers to be of any clinical utility, systematic analysis of the maternal serum should be conducted.
引用
收藏
页码:4410 / 4419
页数:10
相关论文
共 30 条
[1]   Chromosome 21 and Down syndrome: From genomics to pathophysiology [J].
Antonarakis, SE ;
Lyle, R ;
Dermitzakis, ET ;
Reymond, A ;
Deutsch, S .
NATURE REVIEWS GENETICS, 2004, 5 (10) :725-738
[2]  
Berndt P, 1999, ELECTROPHORESIS, V20, P3521, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3521::AID-ELPS3521>3.0.CO
[3]  
2-8
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   Haemostatic changes in pregnancy [J].
Brenner, B .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :409-414
[6]   Perlecan maintains the integrity of cartilage and some basement membranes [J].
Costell, M ;
Gustafsson, E ;
Aszódi, A ;
Mörgelin, M ;
Bloch, W ;
Hunziker, E ;
Addicks, K ;
Timpl, R ;
Fässler, R .
JOURNAL OF CELL BIOLOGY, 1999, 147 (05) :1109-1122
[7]   Etiology and pathogenesis of preeclampsia: Current concepts [J].
Dekker, GA ;
Sibai, BM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (05) :1359-1375
[8]   Proteomics as a tool for clinically relevant biomarker discovery and validation [J].
Duncan, MW ;
Hunsucker, SW .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2005, 230 (11) :808-817
[9]  
Freidl M, 2001, J NEURAL TRANSM-SUPP, P47
[10]   Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro [J].
French, MM ;
Smith, SE ;
Akanbi, K ;
Sanford, T ;
Hecht, J ;
Farach-Carson, MC ;
Carson, DD .
JOURNAL OF CELL BIOLOGY, 1999, 145 (05) :1103-1115